文章：

信使RNA疫苗在非小细胞肺癌治疗中的进展与挑战

Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC

原文发布日期：26 November 2023

DOI: 10.3390/cancers15235589

类型: Article

开放获取: 是

英文摘要：

The introduction of immune checkpoint inhibitors in the therapeutics of non-small cell lung cancer (NSCLC) has been a game-changer in the management of patients with lung cancer; however, challenges do exist since a non-negligible subset of patients does not respond to therapy. Various immunotherapeutic anticancer strategies have been increasingly developed in recent years, including monoclonal antibodies, adoptive T-cell therapy, and vaccines. Fueled by their rapid drug development and successful implementation during the COVID-19 pandemic, messenger RNA (mRNA) vaccines represent an emerging therapeutic approach in other fields of medicine, including oncology. Several clinical trials are currently being conducted to assess the safety and efficacy of mRNA vaccines regarding a variety of solid tumors. Combining mRNA vaccines with other immunotherapeutic approaches has also been suggested and is currently under investigation. Although, in the case of NSCLC, the investigation is still in its early stages, the initial results raise the need for clinician awareness of these promising therapies. To this end, in the present review, we aim to summarize current advances in the development of mRNA vaccines in NSCLC therapeutics and discuss pragmatic challenges regarding their drug development and the different opportunities for implementation.

摘要翻译： 

免疫检查点抑制剂在非小细胞肺癌治疗领域的应用，彻底改变了肺癌患者的治疗格局；然而挑战依然存在，因为仍有不可忽视的患者群体对治疗无应答。近年来，多种免疫治疗抗癌策略得到快速发展，包括单克隆抗体、过继性T细胞疗法和疫苗疗法。信使RNA疫苗凭借其在COVID-19大流行期间展现的快速研发能力与成功应用经验，现已成为包括肿瘤学在内的其他医学领域新兴治疗手段。目前多项临床试验正在评估mRNA疫苗针对各类实体瘤的安全性与有效性。将mRNA疫苗与其他免疫疗法联用的方案也已提出并处于研究阶段。尽管针对非小细胞肺癌的研究尚处早期阶段，初步成果已提示临床医生需要关注这些具有前景的疗法。为此，本综述旨在总结mRNA疫苗在非小细胞肺癌治疗领域的当前进展，并探讨其药物研发过程中面临的实际挑战及不同的应用前景。

原文链接：

Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC